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1. 
PROBOTCS AND METHODS OF 
OBTAINING SAME 
CROSS REFERENCE TO RELATED 
APPLICATIONS 
This application claims benefit under 35 U.S.C. 119(e) to 
U.S. Application No. 61/491,406 filed May 31, 2011. 
TECHNICAL FIELD 
This disclosure generally relates to microbiology and, 
more specifically, to probiotics. 
BACKGROUND 
The large intestine of humans harbors a complex, cell rich, 
and diverse microbial community consisting of hundreds of 
different bacterial species. Included within this microbiota 
are organisms whose presence is associated with, or that 
contribute to the health of the host, referred to as probiotics. 
Probiotics are defined as microbial cell preparations or com 
ponents of microbial cells that have a beneficial effect on the 
health and well-being of the host. Probiotics have been iden 
tified from a number of different genera including, but not 
limited to, Lactobacilli, Streptococcus and Bifidobacterium, 
which have many species that are indigenous to the human 
digestive tract. 
Probiotics are thought to exert their beneficial effects by 
displacing pathogenic enteric bacteria from the intestinal 
mucosa due, at least, in part, to competitive binding. For 
example, enteric pathogens such as enteropathogenic 
Escherichia coli (EPEC), enterotoxigenic E. coli (ETEC), 
Salmonella enteriditis, Yersina pseudotuberculosis and List 
eria monocytogenes must be able to Successively colonize an 
animals gastrointestinal tract in order to cause disease. 
SUMMARY 
This disclosure describes novel probiotics, and also 
describes novel methods by which such probiotics can be 
obtained. 
In one aspect, a Substantially pure population of bacteria is 
provided, wherein the bacteria is Bifidobacterium adolescen 
tis strain BD1. In some embodiments, the substantially pure 
population of bacteria further includes galactooligosaccha 
ride (GOS). 
In another aspect, a composition comprising Bifidobacte 
rium adolescentis strain BD1 and GOS is provided. In some 
embodiments, the composition further includes a pharmaceu 
tically acceptable carrier. Representative pharmaceutically 
acceptable carrier include, without limitation, a liquid carrier, 
a gel-based carrier, an oleaginous carrier, and an emulsion. 
Typically, Such a composition can be in the form of a powder, 
a granule, a tablet, a capsule, a liquid Suspension, a paste, and 
a Syrup. 
In still another aspect, a foodstuff is provided that includes 
(a) an effective amount of the Substantially pure population of 
bacteria or of the composition and (b) at least one food or feed 
ingredient. In certain embodiments, the at least one food 
ingredient is a dairy product (e.g., yogurt). 
In yet another aspect, a method for establishing or main 
taining a healthy gastrointestinal flora in an animal is pro 
vided. Such a method typically includes administering, enter 
ally, an effective amount of the Substantially pure population 
of bacteria, of the composition, or of the foodstuff. Similarly, 
a method for reducing the effects of a gastrointestinal disease 
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in an animal is provided. Such a method typically includes 
administering, enterally, an effective amount of the Substan 
tially pure population of bacteria, of the composition, or of the 
foodstuff. Representative animals are humans. In some 
embodiments, the effective amount is from about 10 CFU/ 
day to about 10' CFU/day. 
In another aspect, a method of identifying, in Vivo, a micro 
bial strain that has a symbiotic relationship with a prebiotic is 
provided. Such a method typically includes administering at 
least one dose of the prebiotic to at least one subject; collect 
ing a sample comprising gastrointestinal microbiota from the 
at least one Subject; and identifying one or more microbial 
strains that are increased in the sample collected from the 
subject relative to a baseline sample collected from the sub 
ject. In some embodiment, the method further includes iso 
lating the one or more microbial strains that are increased in 
the sample collected from the Subject. In some embodiments, 
the method further includes genotyping the one or more 
microbial Strains that are increased in the sample collected 
from the Subject. In certain instances, the genotyping com 
prises sequencing the 16S rDNA. Representative prebiotic 
include, without limitation, GOS, fructooligosaccharide 
(FOS), and inulin. In some embodiments, the administering 
step includes administering the prebiotic to the at least one 
Subject in sequentially higher doses over time. In some 
embodiments, the administering step lasts for at least a week. 
In some embodiments, the sample is a fecal sample. 
Unless otherwise defined, all technical and scientific terms 
used herein have the same meaning as commonly understood 
by one of ordinary skill in the art to which the methods and 
compositions of matter belong. Although methods and mate 
rials similar or equivalent to those described herein can be 
used in the practice or testing of the methods and composi 
tions of matter, suitable methods and materials are described 
below. In addition, the materials, methods, and examples are 
illustrative only and not intended to be limiting. All publica 
tions, patent applications, patents, and other references men 
tioned herein are incorporated by reference in their entirety. 
DESCRIPTION OF DRAWINGS 
Part A 
FIG. 1 is graphs showing the bifidogenic effect of GOS as 
determined by qRT-PCR for all eighteen subjects (A) and for 
the 9 responders (B). Significance (by ANOVA) is indicated 
at either p-0.05 (*) or p-0.001 (***). 
FIG. 2 is graphs showing the correlation of initial bifido 
bacteria levels (baseline) and the increase of bifidobacteria by 
GOS feeding (from the baseline to the average of the 5 and 10 
g dose levels) as measured by absolute numbers (A) and by 
log increase (B). 
FIG. 3 shows DDGE analysis of fecal microbiota of sub 
jects 1, 2, 3 and 4 (A) and 14, 15, 16 and 17 (B) by DGGE. 
Bands that were significantly affected by the GOS treatments 
are outlined. Abundance scores, as measured by DGGE band 
intensities, from bands C, G, H, I and L, as a function of GOS 
doses (C). Correlation of Bifidobacterium adolescentis band 
intensities from subjects 2, 4, 14, 15 and 17 for all time points 
to cell numbers, as measured by Bifidobacterium genus-spe 
cific qRT-PCR (D). 
Part B 
FIG. 4 is a characterization of the fecal microbiota in 
eighteen Subjects that consumed increasing doses of GOS by 
multiplex pyrosequencing of 16S rDNA tags. A phylogenetic 
tree that encompasses the phylum Actinobacteria is shown 
(A). The tree contains representative sequences of all OTUS 
detected that were significantly affected by GOS in individual 
US 9,125,935 B1 
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Subjects together with sequences of related entries in the 
database. The latter includes both type strains of known spe 
cies and sequences from molecular studies of human fecal 
samples. Sequences were aligned using Muscle 3.6 and the 
trees were constructed using the neighbor-joining algorithm 
with 1,000 bootstrap replicates in MEGA 4.0. The sequences 
from individual Subjects are labeled using open black and 
closed black symbols, and type strains and other sequenced 
human strains are indicated by grey symbols. Those OTUs 
that were not significantly affected in all eighteen Subjects 
were labeled as “No significance'. Graphs to the right of the 
trees show the abundance of the OTUs and bacterial groups 
that were significantly affected by GOS. The abundances of 
all of the Bifidobacterium species affected by GOS consump 
tion, for all eighteen Subjects, are shown in B. These graphs 
show mean proportions of the three individual samples taken 
during the treatment periods for each Subject. Baseline and 
washout refer to samples taken in periods where no GOS was 
consumed. Repeated measures ANOVA in combination with 
a Tukey's post-hoc test were performed to indentify differ 
ences between treatment and control periods, where 
*=p-0.05, **=p<0.01, and ***=p-0.001. Baseline and wash 
out periods were not included in the statistic analysis. 
FIG. 5 is a bubble plots showing differences in the propor 
tions of bacterial taxa as a percentage of the entire bacteria 
population detected during consumption of 5.0 g (A) and 10.0 
g (B) when compared to the control period. The size of the 
bubbles is representative of the percent difference. Black 
ovals represent increases in proportions observed during the 
GOS consumption period; white ovals represent decreases. 
FIG. 6 shows the temporal dynamics of the human fecal 
microbiota in response to the consumption of increasing 
doses of GOS shown in five human subjects. Graphs on the 
left show proportions of the three main phyla (Actinobacteria, 
Firmicutes, and Bacteroidetes) and two genera (Bifidobacte 
rium and Bacteroides) that were affected in subjects consid 
ered as “responders'. Graphs on the right show proportions of 
the same three phyla and two genera for Subjects considered 
as “non-responders'. 
FIG. 7 describes the characterization of the fecal micro 
biota in eighteen Subjects that consumed increasing doses of 
GOS by multiplex pyrosequencing of 16S rDNA tags. Phy 
logenetic trees that encompass the phyla, Firmicutes (A) and 
Bacteroidetes (B) are shown. The trees contain representative 
sequences of all OTUs that were significantly affected by 
GOS in individual subjects together with sequences of related 
entries in the database (which included both type strains of 
known species and sequences from molecular studies of 
human fecal samples). Sequences were aligned in Muscle 3.6 
and the trees were built using the neighbor joining algorithm 
with 1,000 bootstrap replicates in MEGA 4.0. Open black, 
closed black, and grey symbols were used to label sequences 
from individual subjects. OTUs that were not significantly 
affected in any of the eighteen subjects were labeled as “NS'. 
Arrows to the right of each cluster indicate the number of 
subjects that showed statistical significance after ANOVA 
analysis. The direction of the arrow indicates either a signifi 
cant increase () or significant decrease () for each subject 
showing significance for that particular OTU cluster. 
FIG. 8 shows that twenty-two anaerobic bacteria of human 
gastrointestinal origin were screened in vitro to determine 
their ability to utilize GOS. Average optical densities and 
standard deviations for each of the strains are shown, with 
GOS-grown cultures in shaded bars and control cultures in 
open bars. Significant differences were determined by stu 
dents T-test and indicated by asterisks, where p-0.05. 
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Part C 
FIG. 9 shows the characterization of the Bifidobacterium 
biota in fecal samples from a human Subject consuming GOS 
and in vitro GOS fermentation of a subsequently isolated 
Bifidobacterium strain. (A) Proportion of bifidobacteria in the 
fecal microbiota as determined by pyrosequencing. Chews 
with four increasing doses (0, 2.5, 5, and 10 g) of GOS were 
consumed in Succession, each for three weeks. Analyses of 
fecal samples collected weekly are shown. (B) Proportion of 
Bifidobacterium lineage spp. II in the same fecal microbiota 
as determined by pyrosequencing. (C) Total numbers of bifi 
dobacteria in the same fecal samples as determined by qRT 
PCR. (D) Growth of Bifidobacterium adolescentis BD1 on 
GOS, lactose, and basal MRS medium without added carbo 
hydrates. 
FIG. 10 is a representation of the timeline for stool and 
urine collection. 
DETAILED DESCRIPTION 
The present disclosure provides methods of selecting and 
isolating one or more microbial strains that are naturally 
occurring in the gastrointestinal microbiota and that exhibit 
improved characteristics in the presence of a prebiotic. Fol 
lowing isolation and characterization, the in vivo-Selected 
microbial strain can be used as a probiotic and, along with the 
prebiotic, can be administered as a Synbiotic composition to 
an animal. For purposes herein, gastrointestinal microbiota 
refers to the microbial population that is present in the gas 
trointestinal tract of a Subject. The gastrointestinal tract typi 
cally includes the mouth, esophagus, stomach, Small intes 
tine, large intestine, rectum and anus. 
As described herein, methods are provided in which a 
microbial strain that is naturally present in the gastrointestinal 
microbiota of one or more subjects can be specifically 
selected for based on its positive response to the presence of 
a prebiotic. Such methods typically start with the administra 
tion of a prebiotic to a subject. As used herein, a Subject can 
refer to a human or a non-human. Representative non-human 
Subjects include, without limitation, livestock (e.g., Swine, 
cow, horse, goat, and sheep), poultry (e.g., fowls such as 
chicken and turkey), and companion animals (e.g., pets Such 
as dogs and cats). 
Prebiotics are defined in the art as an “ingredient that 
allows specific changes, both in the composition and/or activ 
ity in the gastrointestinal microbiota that confers benefits 
upon host well-being and health' (see, for example, Rober 
froid, 1998, Br. J. Nutr., 80:S197-202). Well characterized 
prebiotics include, for example, galacto-oligosaccharide 
(GOS), fructooligosaccharide (FOS), and inulin. GOS and 
FOS refer to a group of oligomeric, non-digestible carbohy 
drates that are produced from lactose using beta-galactosi 
dases to catalyze transgalactosylation reactions. These beta 
linked glycosides are recalcitrant to digestion by host 
secreted enzymes in the Small intestine. Such that they reach 
the colon intact and are available to the colonic microbiota. It 
would be understood by those skilled in the art that other 
compounds that fall within the definition of a prebiotic also 
can be used in the methods described herein. 
Typically, a subject is administered (e.g., asked to ingest) at 
least one dose of the prebiotic but, more often, a number of 
doses overa period of time (e.g., one or more doses per day for 
multiple days (e.g., for about or at least a week, for about or at 
least two weeks)). In some instances, to help or further vali 
date the correlation between an increase in a microbial strain 
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and the presence of a prebiotic, the Subject can be adminis 
tered (e.g., asked to ingest) a prebiotic in sequentially higher 
doses over time. 
At selected points while the Subject is ingesting the prebi 
otic, Samples that contain gastrointestinal microbiota are col 
lected from the Subject. In most instances, the sample is a 
fecal sample, but other samples, provided they contain gas 
trointestinal microbiota, are suitable for use in the methods 
described herein (e.g., an enema wash, a sample taken during 
a colonoscopy). It would be understood by those skilled in the 
art that, for comparison purposes, at least one baseline sample 
needs to be obtained from each subject. As used herein, a 
baseline sample refers to a sample that is taken or obtained 
from the subject before any prebiotic is ingested or following 
a sufficient time period after the prebiotics are no longer 
ingested. Obviously, multiple baseline samples can be 
obtained from the same subject. 
Of particular interest are the microbial strains that increase 
in the presence of the prebiotic compared to, for example, one 
or more baseline samples. Standard laboratory methodolo 
gies are routinely used to identify the genera that are present 
in the gastrointestinal microbiota. These methods can include 
gram staining, differential culture conditions (e.g., utilizing 
different culture media under aerobicfanaerobic conditions at 
different, temperatures), immunological assays, and/or 
MALDI-TOF. In addition, routine laboratory methodologies 
can be used to isolate one or more microbial strains that are 
increased in a Subject in the presence of the prebiotic. As used 
herein, “isolated’ refers to a population of microbial cells in 
which at least about 80% (e.g., about 85%, 90%, 95%,99% or 
100%) of the cells are the B. adolescentis BD1 strain 
described herein. 
In some instances, following the culture methods of iden 
tification, one or more methods of genotyping can be used to 
further confirm the genus and/or genus and species of one or 
more microbial strains. Because they are extremely highly 
conserved, the genes encoding the rRNA sequences (rDNA) 
are routinely used to determine taxonomy as well as phylog 
eny and rate of divergence. For example, PCR with restriction 
fragment length polymorphism (RFLP) of the 16S rDNA can 
be used to genotype microorganisms (see, for example, 
Urakawa et al., 1997, FEMS Microbiol. Lett., 152:125-32), 
sequencing of the 16S rRNA can be used to genotype micro 
organisms (see, for example, Weisburg et al., 1991, J. Bacte 
riol., 173:697-703), or mass spectroscopy of cleaved 16S 
rDNA or rRNA can be used to genotype microorganisms (see, 
for example, Jackson et al., 2006, BMC Bioinformatics, 
7:321). These methods are routinely used in microbiology 
and are continually being modified and improved upon; the 
methods described herein are not to be limited by any par 
ticular methods used to genotype microorganisms. 
Using the methods described herein, a microbial strain can 
be identified, based on in vivo selection, that increases in 
number or otherwise responds positively to the presence of a 
prebiotic. In addition to an increase in number of one or more 
microbial strains in the presence of a prebiotic relative to a 
baseline sample, a "positive response' can refer to, for 
example, an increase in metabolic activity by the microbial 
strain (i.e., in the absence of an increase in number) or both an 
increase in number and an increase in metabolic activity. 
As described herein, this method has been used to identify 
a microbial strain that responds particularly well in a number 
of subjects to the prebiotic, GOS. This microbial strain was 
identified as a Bifidobacterium adolescentis strain, and was 
assigned the designation BD1. This strain was deposited with 
the American Type Culture Collection (ATCC, 10801 Uni 
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versity Blvd., Manassas, Va. 20110) on Oct. 8, 2013, and 
assigned Accession No. PTA-120614. 
The B. adolescentis BD1 strain or other strains identified 
using the methods herein can be provided as a Substantially 
pure population. As used herein, a “substantially pure popu 
lation of cells means that at least about 50% (e.g., about 
55%, 60%. 65%, 70%, 75%, 80% or greater) of the cells 
present are the B. adolescentis BD1 strain described herein. 
Methods of culturing B. adolescentis are well known to those 
of skill in the art. See, for example, Handbook of Culture 
Media for Food Microbiology, 2" Ed., Vol 37, Corry et al., 
eds., 2003, Elsevier Science. In addition, there is a commer 
cially available selective medium defined specifically for cul 
turing Bifidobacterium (e.g., BD Bifidobacterium Agar from 
Becton, Dickinson & Co.). 
After selecting, identifying and isolating a microbial strain 
using the methods disclosed herein, and after confirming the 
microbial strains affinity for the prebiotic, the microbial strain 
can be administered to an animal (e.g., as a probiotic). Given 
the method by which the microbial strain was obtained, it is 
preferred that the microbial strain be administered to an ani 
mal in conjunction with the corresponding prebiotic. In some 
embodiments, the microbial strain and the prebiotic are com 
bined prior to administration to produce a symbiotic. Typi 
cally, the animal that is administered the rationally-designed 
synbiotic is of the same species as the subject from which the 
microbial strain originally was identified. As described above 
with respect to the Subjects, the animal can be a human or any 
number of non-human animals. 
In some embodiments, the microbial strain and the prebi 
otic (e.g., the Synbiotic) can be contained within a foodstuff. 
Foodstuffs include any number of food products that are 
Suitable for human consumption Such as, without limitation, 
milk, yogurt, juices, water, cereals, chewing gum, crackers, 
candies, cookies, vitamin Supplements, meats, and fruits or 
Vegetables (i.e., blended fruits or vegetables Such as, e.g., 
baby food). Foodstuffs also include feed products (e.g., suit 
able for consumption by livestock or companion animals) 
including dry animal feeds. In certain embodiments, the B. 
adolescentis microbial strain described herein along with 
GOS can be mixed into liquid feed or drinking water, or 
combined with a carrier and applied to solid feed. 
A composition or a foodstuff that includes the microbial 
strain (e.g., B. adolescentis BD1) and the prebiotic (e.g., 
GOS) as described herein can include a pharmaceutically 
acceptable carrier. A pharmaceutically acceptable carrier 
should be non-toxic to the bacteria and to the animal, and also 
can include an ingredient that promotes viability of the micro 
organism during storage. Liquid or gel-based carriers are well 
known in the art, such as water, fruit juice, glucose or fructose 
Solutions, physiological electrolyte solutions, and glycols 
Such as methanol, ethanol, propanol, butanol, ethylene glycol 
and propylene glycol. Carriers also include oleaginous carries 
Such as, for example, white petrolatum, isopropyl myristate, 
lanolin or lanolin alcohols, mineral oil, fragrant or essential 
oil, nasturtium extract oil, Sorbitan mono-oleate, cetylstearyl 
alcohol, hydroxypropyl cellulose (MW=100,000 to 1,000, 
000), or detergents (e.g., polyoxyl Stearate or sodium lauryl 
sulfate). Other suitable carriers include water-in-oil or oil-in 
water emulsions and mixtures of emulsifiers and emollients 
are provided. 
A composition or a foodstuff that includes the microbial 
strain (e.g., B. adolescentis BD1) and the prebiotic (e.g., 
GOS) as described herein also can include natural or syn 
thetic flavorings and food-quality coloring agents, thickening 
agents such as corn starch, guar gum, Xanthan gum and the 
like, binders, disintegrators, coating agents, lubricants, stabi 
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lizers, Solubilizing agents, Suspending agents, excipients, and 
diluents. Additional components also can be included that, for 
example, improve palatability, improve shelf-life, and impart 
nutritional benefits. It would be understood by those in the art 
that any additional components in a composition must be 
compatible with maintaining the viability of the microbial 
strain. 
Administration of a composition or a foodstuff that 
includes the microbial strain (e.g., B. adolescentis BD1) and 
the prebiotic (e.g., GOS) as described herein can be accom 
plished by any method that delivers at least a portion of the 
microorganisms and prebiotic into the digestive tract of an 
animal. Therefore, enteral administration is preferred (e.g., 
orally, Sublingually, or rectally), although other routes are not 
excluded. Generally, the formulation of a composition is 
dependent upon its intended route of delivery. For example, a 
composition that includes the B. adolescentis BD1 strain 
(with or without GOS) as described herein can be formulated 
as a powder, a granule, a tablet, a capsule, a liquid Suspension, 
a paste, or a Syrup. 
An effective amount of the microbial strain (i.e., a probi 
otic) described herein is an amount that achieves a desired 
result (e.g., treatment or maintenance) in the absence of a 
toxic, immunological, or allergic reaction in the animal. An 
effective amount can be at least 10" viable colony forming 
units perday (CFU/day; e.g., at least 10 CFU/day, 10 to 10'’ 
CFU/day, or 10' CFU/day), which can be administered in a 
single dose or over multiple doses (e.g., over days, weeks, 
months or years). When the microbial strain described herein 
is administered over a long period of time (e.g., to maintain a 
healthy gastrointestinal flora), the effective amount may be 
less than the foregoing range (e.g., 10 CFU/day to 10 CFU/ 
day). It would be understood by those in the art that the 
Bifidobacteria strain described herein can be administered in 
an amount that exceeds the foregoing range as many Bifido 
bacteria strains are considered to be highly safe and have been 
given GRAS (Generally Recognized As Safe) status by the 
U.S. Food and Drug Administration (FDA). It would be 
appreciated by those skilled in the art that, in the presence of 
the prebiotic, the effective amount (i.e., the amount that 
achieves a desired result) may be reduced and/or the thera 
peutic effect may be increased with the same or less amount. 
Probiotics are reported to produce health benefits which 
include (1) alleviation of intestinal disorders such as consti 
pation and diarrhea caused by infection by pathogenic organ 
isms, antibiotics, or chemotherapy; (2) stimulation and 
modulation of the immune system; (3) anti-tumor effects due 
to inactivation or inhibition of carcinogenic compounds in the 
gastrointestinal tract by reduction of intestinal bacterial 
enzyme activities such as beta-glucuronidase, azoreductase, 
and nitroreductase; (4) reduced production of toxic end prod 
ucts Such as ammonia, phenols and other metabolites of pro 
tein known to influence liver cirrhosis (5) reduction in serum 
cholesterol and blood pressure; (6) maintenance of mucosal 
integrity; (7) alleviation of symptoms of lactose intolerance; 
(8) prevention of vaginitis. Accordingly, the beneficial effects 
attributed to probiotics include increased resistance to infec 
tious diseases, healthier immune systems, reduction in irri 
table bowel syndrome, reductions in blood pressure, reduced 
serum cholesterol, milder allergies and tumor regression. In 
animals, for example, probiotics can enhance weight gain or 
weight loss and improve meat quality, and milk production. 
Significantly, probiotics can be used to establish and maintain 
a healthy (e.g., balanced) gastrointestinal flora in an animal 
and to reduce the effect of gastrointestinal diseases. Gas 
trointestinal diseases include, without limitation, diarrhea, 
constipation, loose stool, abdominal inflation, ulcerous coli 
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tis, Crohn's disease, irritable bowel syndrome, hypersensitive 
intestinal syndromes, food toxicity, food allergy, 
pseudomembranous colitis, hemorrhagic colitis, gastritis, 
gastroduodenal ulcer, dental caries, and periodontitis. See, for 
example, Vaughan, Gastrointestinal Microbiology, 2006, 
CRC Press. Specifically, Bifidobacteria may prevent or 
reduce the effects of metabolic disorders such as obesity and 
type 2 diabetes by reducing gut permeability. Reducing gut 
permeability can improve metabolic endotoxemia and meta 
bolic inflammation, both of which are involved in obesity and 
related metabolic disorders. 
In some embodiments, the microbial strain described 
herein, with or without a prebiotic, can be administered with 
one or more additional probiotic microbial strains. Examples 
of additional probiotic microorganisms that can be used 
include yeasts Such as Saccharomyces, Candida, Pichia and 
Torulopsis, moulds Such as Aspergillus, Rhizopus, Mucor, 
and Penicillium and bacteria Such as the genera Lactobacil 
lus, Bifidobacterium, Clostridium, Leuconostoc, Bacteroi 
des, Staphylococcus, Lactococcus, Bacillus, Streptococcus, 
Fusobacterium, Propionibacterium, Enterococcus, Pedio 
coccus, and Micrococcus. Representative examples of addi 
tional probiotic microorganisms that can be used include 
Saccharomyces cereviseae, Bacillus coagulans, Bacillus 
licheniformis, Bacillus subtilis, Bifidobacterium bifidum, 
Bifidobacterium infantis, Bifidobacterium longum, Entero 
coccus faecium, Enterococcus faecalis, Lactobacillus acido 
philus, Lactobacillus alimentarius, Lactobacillus casei, Lac 
tobacillus curvatus, Lactobacillus delbruckii, Lactobacillus 
johnsonii, Lactobacillus farcininus, Lactobacillus gasseri, 
Lactobacillus helveticus, Lactobacillus rhamnosus, Lactoba 
cillus sake, Lactococcus lactis, Micrococcus varians, Pedio 
coccus acidilactici, and Staphylococcus xylosus. 
The microbial strain described herein can be provided in an 
article of manufacture (e.g., in lyophilized form), with or 
without a prebiotic. An article of manufacture also can 
include one or more pharmaceutically acceptable carriers 
(e.g., a solvent), and further can include one or more tools for 
combining and mixing the microorganism with the prebiotic 
and/or the pharmaceutically acceptable carrier or administer 
ing the composition (e.g., a stick or a straw). In addition, an 
article of manufacture can include one or more other probiotic 
microorganisms. An article of manufacture also can include 
appropriate packaging material, and may include written 
directions or instructions for use (e.g., dosage information) or 
for administration. 
In accordance with the present invention, there may be 
employed conventional molecular biology, microbiology, 
biochemical, and recombinant DNA techniques within the 
skill of the art. Such techniques are explained fully in the 
literature. The invention will be further described in the fol 
lowing examples, which do not limit the scope of the methods 
and compositions of matter described in the claims. 
EXAMPLES 
Part A 
Example 1 
Preparation of Chocolate Chews 
Chocolate-flavored chewable candies (chews) containing 
GOS and control chews (with no GOS) were prepared at the 
University of Nebraska-Lincoln Food Processing Center. The 
GOS used was PurimuneTM, a high purity GOS powder 
(91.8% on a dry basis) provided by GTC Nutrition (Golden, 
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Colo.). The balance of the GOS contained lactose (7%), glu 
cose (<1%), and galactose (<0.5%). The chocolate chews 
were formulated to contain 1.25 g of GOS per 6 g chew. 
Additional corn syrup and Sucrose were included in the con 
trol chews containing no GOS. The formulations of both the 
GOS and control chew are shown in Table 1. Chews were 
wrapped individually in wax paper and stored in sealed plas 
tic bags at 20°C. The chews were distributed to subjects on a 
weekly basis. 
TABLE 1. 
Control chocolate GOS chocolate 
Ingredient chew chew 
Water 1162 11.54 
Sugar 27.35 1942 
GOS (Purimune) O.OO 23.40 
Corn syrup 44.84 31.83 
Palm Kernel oil 7.62 541 
Chocolate liquor 7.58 7:44 
(1/2 bakers) 
Lecithin 0.55 O.S3 
Vanilla 0.44 O43 
Example 2 
Experimental Design 
The study included 21 healthy human volunteer subjects 
that were recruited on the University of Nebraska-Lincoln 
campus. None of the Subjects had been on antibiotics or on a 
vegetarian diet within three months prior to the start of the 
study or during the study. Subjects were allowed to maintain 
their normal lifestyles without any additional restrictions on 
their diets. Two subjects dropped out of the study for reasons 
unrelated to the experiment and one subject was released 
from the study due to pregnancy. Thus, a total of eighteen 
subjects, 13 males and 5 females, between the ages of 19 and 
50 years old, completed the study. The study was conducted 
over a 16 week period. A two-week baseline period (no chews 
administered) was conducted at the beginning of the study, 
followed by four sequential testing periods during which 
chews were administered for three weeks with GOS dosages 
at levels of 0.0g, 2.5 g. 5.0 g, and 10.0 g GOS per day. 
Subjects were blinded in terms of the dose of GOS they 
received, and instructed to consume eight chews per day 
during each testing period, with the only difference being the 
number of GOS-containing chews included in the daily regi 
men, which could not be differentiated from control chews. 
Thus, during the control period, 8 control chews were con 
sumed, and during the 2.5 g treatment period, 2 GOS chews 
(each containing 1.25 g GOS) and 6 control chews were 
consumed. The 5 g treatment period included 4 GOS and 4 
control chews and the 10 g treatment consisted of 8 GOS 
chews. A final two-week washout period (no chews) was 
performed at the end of the fourth testing period. All of the 
dosages were sequential with no washout periods between 
dosages. Subjects were asked to report the presence, absence, 
and severity of gastrointestinal symptoms experienced 
throughout each week of the study. The symptoms Survey was 
based on previously reported studies (Bouhnik et al., 1997, 
Am. J. Clin. Nutr., 69:980-91; Bouhnik et al., 2004, Am. J. 
Clin. Nutr, 8.0:1658-64; and Shadid et al., 2007, Am. J. Clin. 
Nutr., 86:1426-37) and included bowel movement, stool con 
sistency, discomfort, flatulence, abdominal pain, and bloat 
ing, and were scored on a one (none, normal, good well 
being) to five (severe symptoms and discomfort) scale 
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provided as part of weekly subject diaries. The study was 
approved by the Institutional Review Board of the University 
of Nebraska. 
Example 3 
Collection and Processing of Fecal Samples 
Fecal samples were collected weekly from each subject. 
Each sample was processed within 1 hour of a bowel move 
ment. All fecal samples (1.0 g) were weighed and diluted 
10-fold with sterile phosphate buffered saline (PBS; pH 7.0). 
Samples were homogenized and immediately frozen at -80° 
C. and saved for DNA extraction. Fecal samples (1.0 g) were 
also immediately introduced into an anaerobic chamber (Bac 
tron IV Anaerobic Chamber. Shel Lab, Cornelius, Oreg.) and 
a 10-fold dilution series was made with pre-reduced sterile 
saline (0.9% NaCl). Aliquots were plated on Brain Heart 
Infusion Agar (Becton Dickinson; BD, Franklin Lakes, N.J.) 
for total anaerobes (incubated 48 h), Rogosa SL (BD) for 
Bifidobacterium (96 h), and Bacteroides Bile Esculine Agar 
(BD) for Bacteroides (48 h). All plates were incubated 
anaerobically at 37°C. In addition, the Rogosa SL agar plates 
that were used to enumerate bifidobacteria were also exam 
ined at 48 h to estimate lactobacili levels. Serial dilutions 
were also used to plate aliquots aerobically on MacConkey 
Agar (BD) for enterobacteria (24 h), and Bile Esculin Azide 
Agar (Acumedia, USA) for enterococci (48 h). Plates were 
incubated aerobically at 37°C. These organisms were chosen 
for cultural enumeration based on previous prebiotic and 
probiotic feeding studies (Tannock et al., 2000, Appl. Envi 
ron. Microbio., 66:2578-88; Tannocket al., 2004, Appl. Envi 
ron. Microbio., 70:2129-36). 
The fecal pH was measured in aqueous slurries using an 
Ag/AgCl pH meter (Accumet Basic AB15 pH meter, Fisher 
Scientific). Statistical analysis was completed using a one 
way ANOVA as well as Tukey's post-hoc pair-wise compari 
SOn test. 
Example 4 
DNA Extraction 
A 1 mL aliquot of a 1:10 diluted fecal sample in PBS was 
transferred to sterile bead beating tubes (Biospec products, 
Bartlesville, Okla.) containing 300 mg of zirconium beads 
(0.1 mm). Fecal cells were washed three times in chilled PBS 
using centrifugation at 6,000xg for 5 min. Pellets were resus 
pended in 100 uLoflysis buffer (200mMNaCl, 100mM Tris, 
20 mM EDTA, 20 mg/mL Lysozyme, pH 8.0) and incubated 
at 37° C. for 30 min. Buffer ASL (1.6 mL) from the QIAamp 
DNA Stool Mini Kit (Qiagen, Hilden, Germany) was added 
to each sample after the samples were homogenized in a 
MiniBeadbeater-8 (BioSpec Products, OK, USA) for two 
min at maximum speed. The DNA was purified from the 
supernatants using the QIAamp DNA Stool Mini Kit, follow 
ing the Qiagen kit manufacturers instructions. 
Example 5 
Quantitative RealTime-PCR 
Quantitative real time PCR (qRT-PCR) was performed as 
previously described (Martinez et al., 2009, Appl. Environ. 
Microbiol., 75:4175-84) using a Mastercycler Realplex 2 (Ep 
pendorf AG, Hamburg, Germany) with Bifidobacterium-spe 
cific primers F: 5'TCG CGT C(C/T)G GTG. TGA AAG3 
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(SEQ ID NO:1) and R: 5'CCA CAT CCA GC(A/G) TCC Example 7 
AC3 (SEQID NO:2: Martinez et al., 2009, supra; Rinttila et 
al., 2004, J. Appl. Microbiol., 97:1166-77), with an amplicon Statistical Analysis 
size of 243 bp. Standard curves for absolute quantification of 
5 bifidobacteria in the fecal samples were prepared using OVer to determine significance between the different doses of GOS 
night cultures (14 h) of Bifidobacterium animalis ATCC (0, 2.5 g., 5 g, and 10 g) and the control. Baseline/washout 
25527T and Bifidobacterium infantis ATCC 15697T. For samples were combined for the analysis and referred to as 
each qRT-PCR experiment, a standard curve was prepared, in “none'. Statistical analysis was performed for the combined 
duplicate, using DNA extracted from cultures at concentra- data from the eighteen subjects and to identify statistically 
tions ranging from 105-108 CFU/mL. Correlation coeffi- 10 significant increases of individual Subjects. Tukey's test was 
used for post hoc pair-wise comparisons. 
cients for all standard curves were above 0.95. p p p 
One-way ANOVA tests with repeated measures were used 
Example 8 
Example 6 
Digestive Tolerance of GOS 
Analysis by PCR-DGGE 15 All eighteen Subjects completed a weekly symptoms diary 
throughout the duration of the study. These symptoms diaries 
PCR-DGGE was performed as described (Martinez et al., allowed Subjects to rate bowel movement, stool consistency, 
2009, Supra). Briefly, the V3 region of the 16S rRNA gene was discomfort, flatulence, abdominal pain, and bloating on a 
amplified by PCR using universal primers PRBA338fGC scale of one (none, normal, good well-being) to five (severe 
(5'CGC CCGCCGCGC GCG GCG GGC GGG GCGGGG symptoms and discomfort). Based on a one-way ANOVA of 
GCA CGG GGG GAC TCC TAC GGG AGG CAG CAG3; the data, no significant differences were detected for any of 
SEQID NO:3) and PRUN518r (5'ATT ACC GCGGCTGCT the symptoms between the 00 g GOS control dose and any of 
GG'3: SEQ ID NO:4) (Ovreas et al., 1997, Appl. Environ. the GOS treatments (Table 2). A significant symptom change 
was observed for flatulence (p<0.05), but only between the 
Microbio., 63:33.67-73). Denaturing Gradient Gel Electo- 25 baseline and washout and the treatment periods. However, the 
phoresis (DGGE) was performed aS described previously increase in this score occurred not only for the GOS treat 
(Walter et al., 2000, Appl. Environ. Microbio., 66:297-303), ments, but even during consumption of the 0.0 g GOS control 
using a DCode universal mutation detection system (Bio- period. 
TABLE 2 
Mean it standard deviations of weekly symptoms. 
Reported on a scale of 1 (best) to 5 (worst 
Baseline 0.0g 2.5g 5.0 g 10.0 g Washout 
Bowel movement 1.42O55 157 0.61 144 OSS 1.390.51 146 - 0.61 142 (0.79 
Stool consistency 1560.64 1.63 - 0.68 1.54 - 0.68 1.54 - 0.73 1.57 0.65 1.50 - 0.84 
Discomfort 142 O.69 148 0.60 1.56 - O.S7 144 - O.65 1.520.73 1.14 - 0.38 
Flatulence 1520.78 1.83 - 0.75* 1.85 0.79* 1.86 0.75* 2.07 - 0.88: 1.25 O.S.S 
Abdominal pain 1.17 O.38 131 O.49 1.33 O40 130 OSO 1.30 - 0.60 1.14 - 0.41 
Bloating 1.14 - 0.33 1.39 O.75 1.43 O.47 130 O.65 148 - 0.90 1.080.26 
*Significant differences detected by ANOVA (p<0.05) between the GOS and baseline and washout treatments. 
Tukey's post-hoc test did not detect significant differences in pair-wise comparisons, 
Rad, Hercules). Band fragments of interest were excised, Example 9 
repeatedly purified (Walteret al., 2001, Appl. Environ. Micro- as Fecal Bacteria Counts 
bio., 67:2578-85), and then cloned using the TOPORTA Cultural enumerations were performed for total anaerobic 
Cloning R. Kit for Sequencing (pCRR 4TOPOR, Vector) (In- bacteria and for lactose-fermenting enterobacteria, entero 
vitrogen). The QlAprep Spin Miniprep Kit (Qiagen, Hilden, cocci, Bifidobacterium, and Bacteroides. Lactobacili counts 
Germany) was used to isolate plasmids from transformants, were very low (<106/g) throughout the entire duration of the 
study, even during treatment periods. When the data for each 
and inserts were sequenced by a commercial provider. Clos- 50 individual subject was analyzed, the results revealed that for 
est relatives of the partial 16S rRNA sequences were deter- Some Subjects, statistically significant differences in several 
mined using the SeqMatch web tool provided through the of these groups were observed following consumption of 
Ribosomal Database Project (rdp.cme.msu.edu on the World GOS. When the results of all eighteen subjects were pooled 
Wide Web). together, no significant changes were detected for levels of 
Bacteroides, enterococci, or lactose fermenting enterobacte 
BioNumerics software Version 5.0 (Applied Maths) was ria. However, ANOVA revealed that GOS induced a modest, 
used to analyze DGGE profiles. DGGE bands were automati- but statistically significant increase of bifidobacteria com 
cally assigned and densitometric curves were obtained based pared to the control treatment (Table 3). This bifidogenic 
- - - effect occurred when subjects had consumed the 5 g dose of 
on the staining intensity profiles generated by the BioNumer- GOS, and a further increase in dose to 10 g of GOS was not 
ics Software. Band staining intensities were calculated as a 60 significant when compared to the 5g dose. In contrast, how 
percent of each peak area of the entire fingerprint generated ever, the 10g dose did result in a significant increase in total 
for the individual sample. The reliability of this quantification anaerobes compared to the 2.5g dose. In addition, the bacte 
method was previously determined by comparing taxa abun- rial populations that was observed for all groups were similar during the baseline and washout periods. dance inferred by DGGE band intensities with those obtained The pHs of all of the fecal samples (288) were determined. 
with pyrosequencing of 16S rRNA tags in studies on the 65 All but two of the samples had pH values between 60 and 8.0, 
hamster microbiota, and received correlations of ro-0.8 (Mar- and there were no significant treatment differences in pH 
tinez et al., 2009, supra). observed over the period of the study. 
55 
US 9,125,935 B1 
13 
TABLE 3 
14 
Enumeration of bacterial groups through culturing 
Log 10 CFU/g feces (meant SD 
Bacterial Group Baseline O.Og 2.5g 5.0 g 
Lactose fermenting 560 - 1.14 568 1.07 S.64 - 0.86 5.18 126 
Enterobacteria 
Enterococci 5.02 0.99 SO2 - 1.07 4.95 - 0.99 4.67 + O.93 
Bifidobacteria 9.32 0.79 9.48 O.73 96.O. O.80 9.76 O.48* 
Bacteroides 9.S6 0.37 9.58 0.37 9.59 0.35 947 0.32 
Total anaerobes 10.19 O.28, 10.19 O.2O 10.11 - 0.23 10.24 O.15 
Significantly difference to 0.0g: * (p < 0.05), **(p<0.01), **(p<0.001). 
Significantly difference to 2.5g: SSS(p<0.001). 
15 Example 10 
Genus Specific qRT-PCR for Enumeration of 
Bifidobacteria 
2O 
The culture analysis indicated that a bifidogenic effect 
occurred due to consumption of GOS, and that this effect was 
detectable at doses of 5 g and 10g, with no significant differ 
ences between the two high doses. In order to confirm these 
findings without a potential cultivation bias, cell numbers of 
bifidobacteria in fecal samples were quantified by genus 
specific qRT-PCR. As shown in FIG. 1A, the Bifidobacterium 
population in the eighteen subjects increased with the inclu 
sion of chews containing different amounts of GOS. As 
before for cultural enumeration, this increase reached statis 
tical significance when 5g and 10 g of GOS were consumed 
(p<0.001). The analysis also showed major differences in the 
dose response relationships in individual Subjects. In total, 
Bifidobacterium numbers were significantly increased by 
GOS consumption in nine of the eighteen subjects as ana 
lyzed by ANOVA. FIG. 1B shows the numbers of bifidobac 
teria in these nine “responders’. This data showed an equiva 
lent gradual increase of bifidobacteria with dose, with no 
significant differences between 5 and 10 g of GOS. 
To determine if the baseline Bifidobacterium population 
influenced the prebiotic effect, the initial bifidobacteria levels 
was compared between responders and non-responders. The 
Student's t test did not reveal any significant differences 
between these groups, indicating that initial number of bifi 
dobacteria did not determine whether any specific individual 
25 
30 
35 
40 
10.0 g Washout 
S.S9 O.85 5.78 1.17 
4.70 - 0.90 5.13 - 1.10 
9.83 - 0.56*** 9.42 - O.S2 
9.53 0.35 9.53 0.33 
10.35 + 0.16** SSS 10.19 + 0.21 
was a responder or non-responder. In contrast, the baseline 
cell count of bifidobacteria in subjects was a major determi 
nant for the bifidogenic effect when this effect was based on 
the difference in actual numbers from the baseline to the 
average of the 5 and 10g treatments. As shown in FIG. 2A, 
initial levels of bifidobacteria directly correlated with the 
increase of bifidobacteria numbers. However, the bifidogenic 
effect, expressed as the "log increase', was inversely corre 
lated with the initial bifidobacteria levels (FIG. 2B). In other 
words, subjects with low numbers of bifidobacteria had a 
higher potential for the prebiotic to induce a 100-1000 fold 
increase, while Subjects that already possessed high levels of 
bifidobacteria were able to achieve an even higher increase in 
absolute numbers. 
Example 11 
Characterization of Total Fecal Bacterial Populations 
by PCR-DGGE 
To obtain abroader assessment of the impact of GOS on the 
fecal microbiota, a universal PCR-DGGE approach was used 
to determine the dynamics of the community fingerprints. 
These analyses revealed a high level of stability among the 
gut microbiota in all of the subjects. The DGGE gels corre 
sponding to the eight Subjects with the most pronounced 
changes in staining intensities upon consumption of GOS are 
shown in FIG. 3. Quantification of DGGE band intensities 
was then performed using BioNumerics Software, as previ 
ously reported (Martinez et al., 2009, Supra), revealing sev 
eral major effects (Table 4). 
TABLE 4 
Ratio of staining intensities of major bands as proportion of total fingerprint intensity (%). 
Mean band intensity (SD) 
DGGE 
Subject fragment Baseline 0.0 g 2.5g 5.0 g 10.0 g Washout 
Increasing significance 
2 C 3.68 O.O2 2.76 O.OO9 4.87 OO1 6.67 + O.O3 11.89 + 0.04**s 2.93 + O.O2 
4 F 3.13 - O.O2 1.23 O.OO1 383 + O.O2 3.33 O.OOS 6.96 O.O2** 1.39 O.OO2 
G 1.46 OOO7 3.94 O.O2 2.7OOOO4 5.51 O.O1 9.75 + 0.03*ss 1.21 O.OO3 
14 H 3.41. O.16 6.40 OO6 8.57 O.O2 741 - 0.008 8.06 O.O2 O.69 O.O1 
15 I O.OOOOO O.OOOOO 148 O.OO2 2.53 0.01.** 2.55 + 0.002** OOOOOO 
17 L O.92 OOO2 1.73 O.O1 148 OO1 5.150.007 10.00 + 0.03***ssst 0.60 + 0.002 
Decreasing significance 
1 A. 11.91 O.O3 10.73 O.O3 2.79 O.O.S* O.12 O.OO1** O.19 O.OO2** 1.15 O.O1 
B 5.07 - O.O1 350 OO1 3.17 O.O1 2.88 O.OO3 1.03 OOO2 2.51 O.O1 
3 D 6.51 O.O2 7.06 O.O3 42 0.04 130 O.O2 O.OO1 O.OO2 4.50 O.OO4 
US 9,125,935 B1 
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Ratio of staining intensities of major bands as proportion of total fingerprint intensity (%). 
Mean band intensity (tSD 
DGGE 
Subject fragment Baseline O.Og 2.5g 5.0 g 10.0 g Washout 
4 E 1.88 O.OO1 1.66 OOOS 3.35 - O.OO3 2.69 O.O2 0.35 + 0.0009S 2.63 O.O2 
16 J 9.74 O.O3 8.OOOO3 7.15 O.OO9 4.13 O6 4.1OOOOS 4.33 O.OO4 
17 K 8.70 - O.OO2 3.68 0.04 6.79 O.O2 2.80 O.O2 O.63 OOOS 2.83 - 0.004 
Significantly different to 0.0g: *(p<0.05), **(p<0.01), ***(p<0.001). 
Significantly different to 2.5g: S(p<0.05), SS(p<0.01), SSS(p<0.001). 
Significantly different to 5.0 g (p<0.05). 
Subjects 3, 14, 2B, 16, 17K are included because they are approaching significance (p<0.05) at 10g compared to 0.0g, 
The most consistent alteration in band staining intensity 
resulting from consumption of GOS was a band at the bottom 
of the DGGE gels (labeled as C, G, H, I, and L), that was 
present in five subjects, 2, 4, 14, 15, and 17 (FIGS. 3A and 
3B). Excision of the band and subsequent purification and 
DNA sequencing revealed that the band corresponded to Bifi 
dobacterium adolescentis (Table 5). The staining intensity of 
this band clearly showed a dose dependent increase (Table 4), 
although differences were observed between subjects with 
respect to the effective dose (ranging from 2.5-10 g). How 
ever, when the band intensity values from these five subjects 
were averaged, the results revealed that a bifidogenic effect 
occurred only when the GOS dose reached 10 g (FIG. 3C). 
15 
25 
PLoS ONE, 5:e15046). Briefly, the V1-V3 region of the 16S 
rDNA gene was amplified by PCR from fecal DNA using 
primers adapted for the Roche-454 Titanium kit. A mixture 
(4:1) of the primers B-8FM: (5'-CCT ATC CCC TGT GTG 
CCTTGG CAGTCT CAGAGA GTTTGATCMTGG CTC 
AG-3'; SEQID NO:5) and B-8FMBifido: (5'-CCTATCCCC 
TGT GTG CCTTGG CAG TCT CAGAGGGTT CGATTC 
TGG CTCAG-3'; SEQID NO:6), were used as the forward 
primers. The primer A518R: (5'-CCA TCT CAT CCCTGC 
GTG TCTCCG ACT CAGBBBBBBBBATTACCG CGG 
CTG CTGG-3'; SEQID NO:7) containing an 8-basebarcode 
sequence was used as the reverse primer. Sequences were 
then assigned to their respective samples via the barcode. The 
TABLE 5 
Band Closest related GenBank sequence (% similarity between DGGE 
Subject fragment fragment and GenBank sequence) 
1 A. Ruminococcus uncultured bacterium; 29A-b4; DQ905715 (99%) 
2 B Lachnospiraceae uncultured bacterium; RL197 aah88b02; 
DQ794455 (100%) 
C Bifidobacterium adolescentis; E-981074T: niru-5, AF275882 (100%) 
3 D Bacteroides uncultured bacterium; NO48: AY916250 (100%) 
4 E Bacteroides uniformis (T); JCM 5828T; AB050110 (100%) 
F Bacteroides doei (T); JCM 13471; 175; AB242142 (100%) 
G Bifidobacterium adolescentis; E-981074T; nur-5; AF275882 (99%) 
14 H Bifidobacterium adolescentis; E-981074T: niru-5, AF275882 (100%) 
15 I Bifidobacterium adolescentis; E-981074T: niru-5, AF275882 (100%) 
16 J Ruminococcaceae uncultured bacterium; RL185 11 n85a.07; 
DQ825073 (100%) 
17 K Ruminococcus uncultured bacterium; B086; DQ325583 (97%) 
L Bifidobacterium adolescentis; E-981074T: niru-5, AF275882 (100%) 
Collectively, the abundance of B. adolescentis, as deter 
mined by staining intensity, was remarkably quantitative and 
highly correlated to cell numbers as determined by qRT-PCR 
(FIG. 3D). Also, as shown in FIG.3 and Table 4, the increase 
in B. adolescentis was reversible and returned to the baseline 
level within a week of wash out. Consumption of GOS also 
resulted in several other reversible alterations in the fecal 
microbiota; however, most of these alterations related to a 
decrease in staining intensity of bands that corresponded to 
different colonic microorganisms (Table 5). 
Part B 
Example 12 
Analysis of the Fecal Microbiota by Pyrosequencing 
Pyrosequencing of 16S rDNA tags was performed from 
fecal DNA as described previously (Martinez et al., 2010, 
50 
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8FMBifido was used in combination with primer 8FM, as 16S 
DNA sequences within the genus Bifidobacterium are not 
well amplified by the latter primer (Martinez et al., 2009, 
Supra). 
Equal amounts of the PCR products were combined and 
gel purified and then sequenced with the 454/Roche A 
sequencing primer kit using a Roche Genome Sequencer 
GS-FLX. Sequences were binned according to barcodes, 
using the Ribosomal Database Project (RDP) Pyrosequenc 
ing Pipeline (pyro.cme.msu.edu/ on the World Wide Web) 
Initial Process tool (Cole et al., 2009, Nuc. Acids Res., 
37:D141-5). Default parameters were established to remove 
sequences containing any ambiguous nucleotides, except for 
the minimum sequences length, which was set to 300 bp. 
BioEdit Software was used to trim the quality approved 
sequences to 450 bp before Submission to the sequence analy 
ses (see below). 
US 9,125,935 B1 
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Example 13 
Sequence Analyses to Characterize Microbial 
Populations 
Sequences obtained by pyrosequencing were analyzed 
using taxonomy-dependent and taxonomy-independent 
approaches. First, the Classifier tool of the RDP was applied 
(with a minimum bootstrap value of 80%) to obtain a taxo 
nomic assignment of all sequences. The Classifier approach 
allowed a fast determination of the proportions of bacterial 
groups at different taxonomic levels (phylum to genus). Alter 
natively, the sequences were assigned to Operational Taxo 
nomic Units (OTUs). Accordingly, all sequences from each 
subject were individually aligned using the RDP Aligner web 
tool, and then clustered using the RDP Complete Linkage 
Clustering web tool (with a maximum distance cutoff of 97%; 
Cole et al., 2009, supra). The OTU picking was performed on 
a per subject basis, as the entire data set from all of the 
Subjects contained too many sequences for a quality align 
ment. OTUs that contained less than three sequences were 
excluded from the analyses. Using Statistical Analysis Soft 
ware (SAS) to perform ANOVA, the OTUs that were signifi 
cantly affected by the treatments in each subject were identi 
fied. 
Representative sequences from each OTU whose abun 
dance was significantly influenced by GOS were subjected to 
taxonomic classification using SeqMatch, an RDP web tool. 
From each statistically significant OTU identified, five ran 
dom representative sequences were aligned to form consen 
sus sequences using SeqMan Software (DNASTAR Laser 
gene). The consensus sequences were grouped and aligned 
according to phylum (Actinobacteria, Bacteroidetes, Firmic 
utes, Fusobacteria, Proteobacteria, and Verrucomicrobia), 
together with the most closely related type strains or entry in 
the NCBI database using Muscle 3.6 (Edgar, 2004, Nuc. 
Acids Res., 32: 1792-7). Phylogenetic trees were assembled 
by neighbor joining with 1,000 bootstrap replicates with 
MEGA 4.0 Software (Tamura et al., 2007, Mol. Biol. Evol., 
24:1596-9). Using visual analyses and a distance matrix, 
OTUs were assigned as sequence clusters with >97% identity, 
and consensus sequences were generated for each of the OTU 
sequence clusters, as described above. 
Quantification of each OTU in each sample was performed 
by BLASTn analysis with a local database including all the 
quality controlled sequences generated by pyrosequencing. A 
BLASTn algorithm was used with a 97% cutoff (min. length 
300 bp) to quantify each OTU within each sample. The OTUs 
that were closely related to Bifidobacterium adolescentis 
were quantified by BLASTn using a cutoff of 98% (min. 
length 300 bp) as clearly differentiated clusters could be 
identified that showed overlap with 97%. The quantification 
of OTUs in all subjects was then verified to ensure that indi 
vidual sequences were not being assigned to different OTUS. 
In three occasions, OTUs that were initially identified as 
distinct had very high sequence similarities, and were thus 
merged together as single OTUS. 
Example 14 
Determination of Community Diversity 
Two different methods, the generation of rarefaction 
curves and Shannon's index, were applied to determine the 
diversity of the fecal microbiota using 16S rDNA sequence 
data. The DNA sequences within each sample were aligned 
and clustered using RDP web tools Aligner and Complete 
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Linkage Clustering. Individual cluster files corresponding to 
each fecal sample were used to construct Rarefaction curves 
and determine the Shannon's Index. 
Example 15 
Statistical Analysis 
To identify differences in the composition of the fecal 
microbiota induced through dietary treatments (0.0g, 2.5 g. 
5.0 g, and 10.0 g GOS) in all eighteen subjects, one-way 
ANOVA tests with repeated measures were performed. 
Samples obtained during the baseline and washout periods 
were not included within the statistical analysis. Post hoc 
pair-wise comparisons were done using Tukey's method. 
P-values of <0.05 were considered significant unless other 
wise stated. 
Example 16 
In Vitro Utilization of GOS by Bifidobacteria and 
Other Colonic Bacteria 
A total of 39 strains of bifiodbacteria were screened for 
their ability to use GOS as a growth substrate. Included were 
19 lab strains (from ATCC, commercial sources, and the 
Department of Food Science Culture Collection) and 20 iso 
lates obtained from subjects as described above. Strains were 
grown anaerobically at 37°C. in MRS broth containing 2% 
GOS (GTC Nutrition, Golden Colo.). Because the latter 
material contains 92% GOS, with the balance as lactose, 
glucose, and galactose, control cultures were prepared that 
contained an equivalent amount of these Sugars (i.e., 0.16% 
final concentration). In addition, twenty-two anaerobic bac 
teria that were mainly of intestinal origin were also screened 
for their ability to use GOS as a growth substrate. All bacteria 
were obtained from the USDA ARS Culture Collection (Peo 
ria, Ill.) and included strains of Bacteroides thetaiotamicron, 
Bacteroides distasonis, Bacteroides fragilis, Bacteroides uni 
Bacteroides ovatus, Clostridium butyricum, 
Clostridium histolyticum, Clostridium bifermentans, 
Clostridium difficile, Clostridium innocuum, Clostridium 
paraputrificum, Clostridium perfiringens, Clostridium ramo 
sum, Clostridium rumen, Clostridium sporogenes, Entero 
coccus faecalis, Enterococcus faecium, Enterobacter aero 
genes, and Streptococcus salivarius. Bacteria were initially 
propagated in Brain Heart Infusion (BHI) or Reinforced 
Clostridial Agar (RCA). To assess growth on GOS, cells were 
transferred (2%) into a basal medium 5 g/L Peptone No 3 
(BD), 5.0 g/L Casitone (BD), 0.5 g/L L-Cysteine (Sigma), 40 
mL Salt Solution, 10 mL Hemin (Sigma), 900 uLVitamin K3 
(Sigma), and 1 g/L Yeast Extract (BD) containing 1% GOS 
(GTC Nutrition, Golden, Colo.). Control cultures containing 
0.08% mono- and disaccharides were prepared as above. 
All cultures were incubated at 37°C. in an anaerobic cham 
ber (Forma Scientific, Marietta, Ohio) containing an atmo 
sphere of 85% nitrogen, 10% hydrogen, and 5% carbon diox 
ide and assessed for growth by optical density measurement 
at 600 nm in a Beckman Model 640 spectrophotometer. Each 
experiment was done in triplicate and the average optical 
densities were determined. 
Example 17 
The Effect of GOS on the Fecal Microbial 
Communities 
A total of 288 fecal samples were included in this study. 
Pyrosequencing resulted in a total of 2.3 million sequences. 
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After quality control analysis (see Methods), an average of 
8,200 sequences per sample was obtained. The mean 
sequence length was approximately 450 bp. An average of 
2,022 OTUs was identified per subject. To assess the effect of 
GOS on the bacterial diversity in fecal samples, rarefaction 
curves for all eighteen Subjects were generated, and Shan 
non's diversity indices were calculated. This analysis 
revealed that consumption of GOS did not alter bacterial 
diversity of the fecal samples (p<0.0713). 
The overall composition of the gut microbiota in the 18 
individuals included in this study is in general agreement with 
that of previous studies (Turnbaugh et al., 2009, Nature, 457: 
480-4). During the baseline period (no dietary modulation), 
the microbiota was dominated by two phyla, Firmicutes 
(64%) and Bacteroidetes (28%). Other phyla detected 
included Actinobacteria (3%), Verrucomicrobia (1%), and 
Proteobacteria (1%). Approximately 3% of the sequences 
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treatment (0.0 g GOS in confections) had no effect on the 
fecal microbiota, as the microbial populations during this 
period were not significantly different from those during the 
baseline and washout periods (although slight increases in the 
family Bacteroidaceae and the genus Bacteroides were 
detected). In addition, no significant changes in the fecal 
microbiota were detected for a dose of 2.5g GOS. In contrast, 
consumption of 5.0 g GOS led to several significant changes. 
There were significant increases (p<0.05) in the family Bifi 
dobacteriaceae and the genus Bifidobacterium compared to 
the control dose. At the species level, the abundance of only 
one OTU, corresponding to the species, Fecalibacterium 
prausnitzii, increased significantly at this dose. In contrast, 
significant decreases in abundance were observed at both the 
family and genus levels for Bacteroidaceae (p<0.01) and 
Bacteroides (p<0.01), respectively, at the 5.0 g dose com 
pared to the control. 
TABLE 6 
Abundance of bacterial taxa affected by GOS consumption in fecal samples of eighteen 
human Subjects as determined by pyrosequencing of 16S rRNA tags. 
Proportion of bacterial taxa expressed in percentage (Meant SD 
Baseline' 0.0 g’ 2.5g 5.0 g’ 10.0 g? Washout P value 
Phylum 
Actinobaceria 2.52 234 2.58 3.59 3.69 433 5.39 6.11 7.198.88 2.09 - 2.51 <O.OOO1 
Family 
Bifidobacteriaceae 1.56 2.14 1692.65 2SO - 3.43 4.275.18 6.14 + 7.08***S$ 1.24 + 2.10 <0.0001 
Bacteroidaceae 12.22 7.43 15.03 - 10.66 13.299.24 11.209.11** 11.669.22** 13.698.27 OOO3O 
Genus 
Bifidobacterium 1.281.81 140 - 220 2.13 - 2.99 3.61 - 4.46 5.20 + 6.18:: *S$ 1.05 + 1.82 0.0002 
Bacteroides 12.22 7.43 15.03 - 10.66 13.299.24 11.209.11** 11.669.22** 13.698.27 <O.OOO1 
Species (OTUs) 
bifidobacterium O.37 - O.S6 O.34 - 0.89 0.46 - 0.86 0.85 - 1.09 1.03 - 1.SS* O.21 - 0.48 OO1O 
adoiscentis 
Bifiobacterium O.15 O.36 O.18 0.33 0.25 + 0.55 0521.13 0.77 - 141*S O.12 0.25 <O.OOO1 
Ssp I 
Bifidobacterium O46 O.94 O.6O 153 0.76 - 172 1412.38 2.00 + 3.45*$ O.220.45 <O.OOO1 
spp II 
Bifidobacterium O.62 - 121 O.78 2.19 O.98 2.02 1823.30 2.50 + 4.55*$ O4O 0.92 OOO88 
spp III 
Bifidobacterium O.09: O23 O.09: 0.23 O.12 0.32 0.22 OSO O.33 O.85* O.15 - 0.38 O.O232 
longtin 
Bifidobacterium O.15 O.34 0.27- 0.88 0.56 - 138 0.51 - 1.16 O.91 2.08** O.28 0.78 O.O1 OS 
cantentiatin 
Faecaibacterium 3.52 2.71 3.21 2.26 3.71 - 2.67 4.37 3.67 3.16 + 1.82 3.422.28 <O.OOO1 
prailsnitzi 
Coprococcits 2.90 2.04 240 1.75 2.12 1.24 1.99 - 155 1.78 1.11* 2.15 - 1.30 <O.OOO1 
COile:S 
Bacteria populations are averages of the two time points of the baseline period and the two time points of the washout 2 period. 
*Bacteria populations are averages of all three time points of the feeding period, 
Bacterial populations during the dietary treatments were compared to each other with repeated measures ANOVA and Tukey's posthoc test, 
Significantly different to 0.00 g. *(p<0.05), **(p<0.01), ***(p<0.001). 
Significantly different to 2.5g: Sop < 0.05), scp < 0.01). 
Significantly different to 5.0 g.: f(p<0.05). 
remained unclassified. At the family level, the predominant 
groups were the Lachnospiraceae (31%), Ruminococcaceae 
(18%), Bacteroidaceae (12%), and Bifidobacteriaceae (2%). 
The most common genera included Bacteroides (12.2%), 
Fecalibacterium (7.7%), Blautia (7.4%), Ruminococcus 
(3.7%), Roseburia (2.2%), Bifidobacterium (1.5%), and 
Dorea (1.3%). 
Sequence proportions determined by pyrosequencing were 
used to determine the effect of GOS on the composition of the 
gastrointestinal microbiota. The groups that were signifi 
cantly affected are shown in Table 6, according to phylum, 
family, genus (by RDP Classifier), and OTUs. The control 
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At the 10.0 g GOS dose, additional differences in the 
proportions of several phyla (using taxonomy-based analy 
sis) were observed (Table 6). There was a significant increase 
in Actinobacteria compared to the control (p<0.001), as well 
as compared to the 2.5 g dose (p<0.05). This change was 
associated with an increase both in the family Bifidobacteri 
aceae, the genus Bifidobacterium, and several OTUs related 
to Bifidobacterium species. Although there were not signifi 
cant differences between the 5 gram and 10 gram dose in 
Bifidobacteriaceae, the genus Bifidobacterium, and Bifido 
bacterium species, the amount of bifidobacteria at 10 gram 
GOS was consistently higher than at 5 gram. In addition, 
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bifidobacteria were significantly increased at 10 gram GOS 
when compared to the 2.5 gram dose (Table 6). Collectively, 
the abundances of bifidobacteria determined by pyrosequenc 
ing were highly correlated (r–0.7629, p<0.0001) with the cell 
counts obtained by qRT-PCR as described above. This sup 
ports previous findings that show that the pyrosequencing 
approach allows a quantitative determination of bifidobacte 
ria in human fecal samples. 
There were few bacterial taxa other than bifidobacteria that 
were influenced by GOS, based on a taxonomy-based analy 
sis (Table 6). Statistically significant decreases were observed 
only within the family Bacteroidaceae (p<0.05) and the genus 
Bacteroides (p<0.05) when compared to the control dose of 
GOS. In contrast, the OTU-based approach identified two 
additional taxa, Coprococcus comes and F. prausnitzii, whose 
abundances differed significantly at 5 and 10g doses. How 
ever, no trend was apparent from these results (Table 6). 
Although few taxa were identified that significantly 
decreased with the administration of GOS when all 18 sub 
jects were assessed collectively, our analysis nonetheless 
showed that different bacterial lineages were decreased in 
individual subjects. As shown in FIG. 7, the changes were 
detected in a small number of subjects and occurred primarily 
within taxonomically diverse members within the phyla Fir 
micutes (FIG.7A) and Bacteroidetes (FIG.7B). Most of these 
taxa were reduced by GOS, but no consistent pattern was 
detected among Subjects. Thus, it appears that although GOS 
induces a rather selective increase of different lineages of 
bifidobacteria, GOS does not resultina consistent increase of 
another bacterial group or a significant decrease of particular 
bacterial groups. 
Example 18 
GOS Enhances Different Lineages of Bifidobacteria 
A BLASTn analysis revealed that eight OTUs had statisti 
cally significant changes in abundance at the 10g GOS dose, 
six of which were assigned to the genus Bifidobacterium. 
Three of the OTUs showed a high similarity (>97%) to 
described Bifidobacterium species, B. adolescentis, B. lon 
gum, and B. catenulatum (Table 6, FIG. 4A). The other OTUs 
(Bifidobacterium spp I, II, and III) showed lower sequence 
similarities (91-96%) to known Bifidobacterium species, and 
the phylogenetic analysis shown in FIG. 4A revealed that 
these OTUs belonged to lineages clearly distinct from known 
type strains. Interestingly, two of these OTUs (Bifidobacte 
rium spp II and Bifidobacterium spp III), showed the numeri 
cally highest response to GOS (Table 6, FIG. 4A). 
Example 19 
The Population Shifts Induced by GOS Vary Among 
Individuals 
Although the consumption of GOS at the higher doses 
resulted in compositional shifts within Subjects on a collec 
tive basis (FIG. 4B), closer examination of samples from 
individual subjects revealed that the effect of GOS on the 
intestinal composition of participants was Subject to consid 
erable variation among individuals (FIG. 5). Indeed, the data 
showed that there were some individuals that were essentially 
unaffected by GOS consumption, whereas other experienced 
significant changes. The most Substantial alteration was the 
increase in the Actinobacteria (at the phylum, family, genus, 
and species levels) which was observed in sixteen of the 
eighteen subjects after 5.0 g and seventeen of the subjects 
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after 10.0 g of GOS. At the genus level, in particular, substan 
tial increases were observed in the abundances of Bifidobac 
terium, which increased approximately ten-fold (from 1-4% 
up to 18-33%) in four subjects (subjects 2, 4, 11, and 17), and 
five-fold in seven additional subjects (subjects 1, 9, 10, 15, 
18). Several culturable isolates (NEGOS 1-3) were obtained 
from these subjects and were found to associate within the 
distinct Bifidobacterium spp. II lineage (FIG. 4A), indicating 
that this GOS responding linage contains bacteria that can be 
cultured. There was a very consistent reduction in the 
Bacteroidetes (at the family, genus, and species levels), which 
occurred within all of the subjects at some point after 5.0 g of 
GOS was consumed (FIG. 5). At the genus level, there was a 
decrease in the abundance of Bacteroides in 17 subjects after 
the 5.0 g GOS dose (all except subject 4), with 14 of those 
subjects having a further decrease after consumption of 10.0 
g of GOS. 
Example 20 
Temporal Dynamics of Microbial Populations in 
Response to GOS 
Analyses of the community profiles provided insight into 
how GOS influenced the population dynamics over the entire 
16 week study period. All of the changes induced by GOS 
were reversible within one week, and no differences (Stu 
dent's t-test, pc-0.05) could be detected in the proportions of 
the bacterial groups between the first washout sample and the 
baseline sample (FIG. 6). The temporal patterns of the three 
main phyla (Actinobacteria, Bacteroidetes, and Firmicutes) 
and two of the selected genera (Bifidobacterium and 
Bacteroides) for five representative subjects showed that 
these groups were stable in their temporal response to GOS. 
For example, levels of Actinobacteria, Bacteroidetes, and 
Firmicutes were remarkably stable in fecal samples at the 
baseline and washout periods, and their populations returned 
to the baseline level within one to two weeks after GOS 
consumption was stopped. The same observations were also 
made at the genus level for Bifidobacterium and Bacteroides. 
Example 21 
In Vitro Growth of Gastrointestinal Microbiota 
Cultures on the Prebiotic GOS 
As shown above, GOS induces alterations to the human 
fecal microbiota that are remarkably specific for bifidobacte 
ria. However, GOS utilization was observed to be a strain 
specific phenotype, at least based on in vitro growth studies 
(Table 7). It was also considered whether or not the ability to 
utilize GOS as a growth substrate was restricted to bifidobac 
teria and absent in other colonic bacteria. Therefore, the abil 
ity of twenty-two strains of bacteria that are associated with 
the human intestinal tract to utilize GOS was tested. This was 
performed by comparing growth in media containing GOS 
with growth in basal medium (i.e., without an additional 
source of carbohydrate). This experiment revealed that 6 of 
the 11 Clostridium strains could utilize GOS (FIG. 8), as 
indicated by higher final cell densities compared to growth 
without carbohydrates. In addition, three of the six strains of 
Bacteroides were also significantly enriched when GOS was 
present. Significant growth on GOS was not observed, how 
ever, for Strains of the genera Enterococcus, Enterobacter, or 
Streptococcus used in this study. 
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TABLE 7 
Number 
negative (%) 
Number 
Species (total number) positives (%) 
B. adolescentis (10) 6 (60) 4 (40) 
B. bifidum (6) 5 (84) 1 (16) 
B. breve (2) 1 (50) 1 (50) 
B. animalis Subsp. Lactis. (1) 1 (100) O 
B. longtim Subsp. Infantis (2) 2 (100) O 
Blongtim Subsp. longtim (9) 6 (67) 3 (33) 
B. pseudocatentiatin (3) 2 (67) 1 (33) 
Other Bifidobacterium spp. (6) 3 (50) 3 (50) 
Total (39) 26 (67) 13 (33) 
Part C 
Example 22 
Summary of Part A and Part B 
Isolates of the genus Bifidobacterium were obtained from 
responders while the Subjects were consuming 10 grams of 
GOS. As shown in FIGS. 9A and 9B, 10 grams of GOS led to 
an increase in the proportion of bifidobacteria in the fecal 
samples of one subject from around 3% to around 20%, and 
an increase of the Bifidobacterium spp. II lineage from around 
3% to 10%, as determined by 16S rRNA tag pyrosequencing. 
Absolute quantification using qRT-PCR confirmed that bifi 
dobacteria numbers increased in the fecal samples of this 
subject through the addition of GOS (FIG. 9C). From this 
subject, three bacterial isolates were obtained from selective 
agar plates (Rogosa SL. Agar) during the consumption of 10 
gram GOS. All three isolates belong to the Bifidobacterium 
spp. II lineage, which showed a marked increase through 
GOS (FIG.9B) and two of these isolates represented the same 
strain based on molecular typing. One isolate, BD1 (97% 
homology to the type strain of Bifidobacterium adolescentis 
when the entire 16S rRNA gene was analyzed), was tested for 
its ability to ferment GOS. As expected for a lineage that 
became enriched in vivo through the administration GOS, 
strain BD1 showed a remarkable ability to utilize GOS, grow 
ing as well as on lactose (FIG. 9D). 
Example 23 
Research Design and Protocol 
The study is organized as a randomized, placebo-con 
trolled, parallel-arm clinical trial conducted at Rush Univer 
sity Medical Center (RUMC) under the supervision of Dr. 
Heather Rasmussen. The trial includes six, 3-week treatments 
using obese (BMI=300-40.0 kg/m) subjects who are healthy 
(but the study allows subjects with elevated liver enzymes due 
to fatty liver and metabolic syndrome). Three-week treatment 
length was selected to allow sufficient epithelial cell turnover. 
A total of 180 subjects are recruited and randomly assigned to 
six groups (n/group=30) as follows: 
Group 1: Placebo (daily dose of 5 gram lactose) 
Group 2: Probiotic 1: 10 cells of B. adolescentis BD1 
Group 3: Probiotic 2: 10 cells of B. animalis subsp. lactis 
BB-12. 
Group 4: Synbiotic 1: InVivoSyn (5 gram GOS plus 10 
cells of B. adolescentis BD1) 
Group 5: Synbiotic 2: 5 gram GOS plus 10 cells of B. 
animalis subsp. lactis BB-12 
Group 6: Prebiotic (5 gram GOS) 
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Three visits are required from each subject. At Visit 1, 
potential subjects are screened foreligibility and are provided 
with a 3-day diet record, all supplies for stool and urine 
collection (stoolkit, urine collection containers, Sugar cock 
tail, and aspirin) and instructions for specimen handling and 
for completing these tasks before the next visit. Each subject 
collects the stool before taking the Sugar cocktail to avoid 
potential effects of sugar cocktail on SCFA and microbiota 
composition. Details of the stool and urine collection are 
shown in FIG. 10. 
In brief, the sugar cocktail is taken at 6 or 7 AM after an 
overnight fast. Subjects collect allurine for 24 hours (first 12 
hour in onejar and second 12 hour in secondjar). The Subject 
repeats the Sugar cocktail ingestion and urine collection 12 
hours after taking 2.6 gram of aspirin to induce intestinal 
permeability. The subject is instructed to store the urine and 
stool samples in Styrofoam coolers with freezer packs until 
delivery to the hospital (not >than 3 days after collection). At 
Visit 2, the study subject provides urine from the aspirin 
challenge and the completed food record; Subjects also have 
their blood drawn for CMP and endotoxin measurements 
(after 8 hour fasting) at this visit. Endotoxin is only assessed 
after aspirin challenge since previous research showed that 
aspirin challenge was necessary to induce hyperpermeability 
in susceptible obese individuals. Additional serum and 
plasma is collected and stored in-80 freezer for future study 
(measurement of lipid profile and insulin to calculate HOMA 
index for metabolic syndrome and cytokines, CRP). Urine is 
stored for future 12-hour cortisol measurements. Subjects are 
provided with one of the six treatments (as determined by 
randomization, see below), supplies for stool and urine col 
lection identical to baseline. Subjects consume their ran 
domly assigned Supplement daily for three weeks as 
instructed. At the end of three weeks (within week 3), subjects 
return to the clinic to provide stool, urine as previously 
described for week 0-1. At the final visit after 3 weeks of 
Supplementation, the Subjects provide the remaining urine 
sample, and 3-day food records. Subjects provide fasting 
blood for endotoxemia and CMP measurements and stored 
serum and complete questionnaires regarding adverse events 
including a questionnaire that rates bowel movement, stool 
consistency, discomfort, flatulence, abdominal pain, and 
bloating on a scale from 1 (best) to 5 (worst). Weight, height, 
waist circumference, and blood pressure is measured, and 
BMI is calculated at each visit. Blood pressure is measured 
using an automated cuff with the average of three assessments 
used for statistical comparisons. In addition, stress is moni 
tored at baseline and treatment end using the validated Per 
ceived Stress Questionnaire as stress alone can increase per 
meability. The necessary protocol approvals are obtained 
from RUMC and UNL's Institutional Review Boards (IRB) 
before initiation of the study, and subjects provide written 
informed consent before any study procedures are performed. 
Example 24 
Subject Compliance and Education 
A training session is held to explain the protocol to the 
Subjects, how to consume the dietary items, the importance of 
compliance, and the need for honesty if adherence to the 
dietary treatment is not met. Subjects are provided with a 
detailed explanation of the required commitment, and they 
are encouraged to indicate to the clinical coordinator any 
diversion from the dietary treatment and to return any prod 
ucts that were not consumed. Regular interaction with the 
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Subjects by weekly phone calls is also encourage compliance. 
Missing data is handled with the Last Observation Carried 
Forward method. 
Examples 25 
Subjects 
Obese subjects (300-40.0 kg/m) are used for this study 
because: (1) over /3 of the population is obese, and (2) these 
individuals are predispositioned to hyperpermeability. An 
equal number of both genders (50% each) are enrolled. It is an 
aim to include approximately 40% minorities (30% African 
American, 10% Hispanic or other minorities) in this study. 
This enrollment of minorities is especially important because 
obesity is especially preponderant in these minority groups. 
Inclusion criteria include healthy subjects 18-60 years with 
a BMI of 30.0-40.0 kg/m. Exclusion criteria include: (1) 
prior intestinal resection, (2) patient history of GI diseases 
except for hiatalhernia, GERD, hemorrhoids, (3) severe renal 
disease defined by creatinine more than twice normal, (4) 
markedly abnormal liver function defined by ALT/AST over 
4 times normal levels or elevated bilirubin (5) antibiotic use 
within the last 12 weeks prior to enrollment, (6) lean or 
overweight (BMI<30 kg/m), (7) intolerant to aspirin, (8) 
regular use of aspirin, (9) excessive alcohol intake (>2 drinks 
for men or 1 drink for women daily), (10) presence of chronic 
metabolic disease (cardiovascular disease, insulin requiring 
diabetes or uncontrolled diabetes, cancer, (11) a plan to have 
a major change in dietary habit during the following 6 
months, (12) consumption of probiotics, prebiotics or Synbi 
otics without an appropriate 4 week washout period, (13) 
lactose intolerance or malabsorption; (14) subjects younger 
than 18 or older than 60, and/or (15) unwillingness to consent 
to the study. 
Examples 26 
Randomization/Stratification/Blinding 
The study participants are randomized (concealed, block 
of 4) to one of the six treatment groups on their second visit 
based on a computer-generated randomization. Randomiza 
tion is stratified for gender and race to ensure equal numbers 
of males and females and racial groups in each of the six 
treatments. The randomization is concealed and remains 
blinded until completion of the study. The statistician also is 
blinded, with the exception of having access to a subjects 
identification numbers that belong to the six randomized 
groups for analysis purposes. The study participants also are 
blinded to the group assignment. The number of Sachets to be 
taken daily and the shape of Sachets is identical in all six 
groups. The Sachets are opaque and their contents are not 
visible. Expectancy and credibility are measured in both pre 
and post-treatment to determine the role that these factors 
play in outcomes, and to confirm that the Subjects were 
blinded. 
Examples 27 
Power and Sample Size 
Analysis showed that 40 subjects are needed for each group 
to reach statistical significance (power-0.85; p<0.05). 
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Examples 28 
Dietary Treatments 
The two organisms that are used in this feeding study are B. 
adolescentis BD1 and B. animalis BB-12. The latter is com 
mercially available from Chrs. Hansen as a high cell density 
powder. Strain BD1 is produced from a contract manufacturer 
(Danwell Technology, Garden Grove, Calif.). Probiotic mix 
tures subsequently are portioned into “sachets” in the Food 
Processing Product Development Lab (UNL). Each sachet 
contains 1 g of cellpowder containing 10 CFU/g. In addition, 
5.5 grams of lactose also is added as a carrier/control (see 
below) for a total dose of 6.5 g. The sachet material is imper 
meable to oxygen and moisture. The prebiotic, GOS, is 
obtained from Corn Products International (sold under the 
trade name, Purimune). This high purity GOS (>91%) con 
tains less than 8% lactose. It was previously established that 
a dose of 5g per day of this GOS was sufficient to induce a 
bifidodogenic response and that a dose as high as 10 g/day did 
not cause side-effects. The GOS is packaged in Sachets con 
taining 5.5 g of Purimune (delivering 5 g of GOS) and an 
additional 1.0 g of lactose, for a total dose of 6.5 g. Synbiotics 
contain 5.5 g of Purimune and 1.0 g of probiotic, either 
Bifidobacterium adolescentis BD1 or Bifidobacterium ani 
malis BB-12, for a total dose of 6.5 g. Placebo samples 
contain 6.5 g of lactose. Subjects are provided with enough 
samples for the entire length of the study. Subjects are 
instructed to consume each dose in a daily basis, either mixed 
with food or liquid. The subjects are instructed to store 
samples in a cool (<25°C.) environment. 
Example 29 
Analysis of Composition Fecal Microbiota 
Frozen fecal samples are thawed and diluted in Phosphate 
Buffered Saline (PBS) in a 1:10 ratio. DNA is isolated and gut 
microbiota composition is analyzed by pyrosequencing of 
16S rRNA tags. Briefly, total microbial DNA is isolated from 
the fecal samples using a procedure that employs both enzy 
matic and mechanical cell disruption. The V1-V3 region of 
the 16S rRNA gene of the bacteria present in the fecal sample 
is amplified by PCR from fecal microbial DNA by using a 
combination of universal PCR primers that target the majority 
of bacteria. The amplicons from each reaction is mixed in 
equal amounts based on concentration and is subjected to 
sequencing using a Roche Genome Sequencer GS-FLX using 
the Titanium platform. This method results in around 300, 
000-500,000 sequence reads per half-run after quality con 
trol, and allows for a detailed characterization of the gut 
microbiota via bioinformatic pipelines. 
Example 30 
Determination of Absolute Cell Numbers of 
Probiotic Strains and Total Bifidobacteria in Fecal 
Samples 
Quantitative real-time PCR (qRT-PCR) is used to quantify 
strains BD1 and BB-12 in human fecal samples. DNA is 
isolated from human fecal samples and qRT-PCR is per 
formed to determine absolute cell numbers of the two strains 
using qPCR with strain specific primers. The primers are 
targeted towards strain specific sequences in the pan-genome 
of the species. The genome of B. animalis subsp. lactis BB-12 
is available, and the genomic sequence of B. adolescentis 
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BD1 is currently being obtained. Total numbers of bifidobac 
teria are determined by qRT-PCR. Absolute quantification by 
qRT-PCR is performed in a Mastercycler realplex real-time 
PCR system using standard curves generated with known cell 
numbers of the two Bifidobacterium strains. 
Example 31 
Short-Chain Fatty Acid Analysis and Energy Content 
Short-chain fatty acids (SCFA), including acetate, propi 
onate, and butyrate, are identified by GC in the Analytical 
Chemistry Lab in the Department of Food Science and Tech 
nology at UNL. 
Example 32 
Determination of Metabolic Activity of Probiotic 
Strains in Human Fecal Samples 
To determine if GOS increases the metabolic activity of the 
Bifidobacterium strains in the human gastrointestinal tract, 
both rRNA and rDNA templates in human fecal samples is 
quantified using species specific primers. This determination 
is based on the premise that metabolic activity in bacteria is 
roughly proportional to the growth rate of the bacteria. While 
DNA-based analytical procedures provide a phylogenetic 
picture of the community, they do not reflect metabolic activ 
ity. The higher the ratio between rRNA to rDNA templates in 
fecal samples, the more metabolically active is the organism. 
Total RNA (and especially ribosomal RNA) is isolated from 
fecal samples. cDNA is prepared from DNAse treated RNA. 
Template amounts are determined using qRT-PCR with spe 
cific primers that target the 23S rRNA gene. The primers are 
based on comparisons of 23 rRNA gene sequences from 
Bifidobacterium adolescentis strains and sequences that are 
available in database. This 23S rRNA gene sequence is vari 
able in B. adolescentis, showing around 2% difference 
between the strains ATCC 15703 and L2-32, allowing the 
development of primers that are, at least to Some degree, 
strain specific. 
Example 33 
Intestinal Permeability Measurement 
One way to assess intestinal permeability is by administra 
tion of oral Sugars and analysis of subsequent Sugar excretion 
in collected urine. Passageways ("pores') formed by tight 
junctions between GI epithelial cells range in size from 4-60 
A and differentially allow the passage of molecules. Small 
molecules Such as mannitol traverse pores of all sizes, while 
larger molecules, such as lactulose, only traverse the larger 
pores. Sucrose is rapidly degraded after leaving the stomach, 
so increased Sucrose excretion reflects gastric permeability 
and Sucralose is absorbed through large pores in the Small and 
large intestine. Since these Sugars are not metabolized sig 
nificantly, excretion into the urine reflects intestinal perme 
ability. Following ingestion of a standard Sugar load, 
increased urinary Sucrose, lactulose/mannitol ratio and 
Sucralose reflects gastroduodenal, Small intestinal and total 
gut (Small bowel and large bowel) hyperpermeability, respec 
tively. Increased Sucralose excretion in the face of normal 
lactulose/mannitol ratio might reflect increased large intesti 
nal permeability. The rationale for using urinary Sucralose as 
a reliable marker of total gut permeability is that not only 
sucralose is relatively uniformly absorbed in both small and 
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large intestine it is also available in the lumen of colon for 
absorption because, unlike lactulose and mannitol, it cannot 
be metabolized and consumed by colonic bacteria. 
Subjects fast overnight and Subsequently ingest a Sugar 
mixture containing 2 grams mannitol. 7.5 grams lactulose, 40 
mg Sucrose and 1 gram Sucralose in the morning, then collect 
2 sequential 12-hour urinations (the first 12 hours for mea 
Surement of lactulose and mannitol, and 24 hours for Sucral 
ose). Urine is analyzed for Sugar content using gas chroma 
tography (GC) techniques. Measurement of urinary Sugars 
using GC is used to calculate intestinal permeability and is 
expressed as percent oral dose excreted in the urine. A method 
is used that involves conversion of the relevant sugars to their 
alditol acetate form. 
While obese individuals are at an increased risk of hyper 
permeability, increases in permeability may not be observed 
unless challenged by other factors such as aspirin or alcohol. 
In order to induce hyperpermeability, Subjects participate in 
an aspirin challenge at baseline and the end of the 3-week 
treatment. Four tablets, each containing 325 mg of aspirin, are 
given 12 h before ingestion of the Sugar mixture and another 
four tablets 1 h before taking the sugar drink. Measurement of 
urinary Sugars using GC is identical to that of the Sugar test 
without aspirin challenge. 
Example 34 
Plasma and Serum Measures of Endotoxin Exposure 
Increased intestinal permeability strongly correlates with 
markers of increased exposure to endotoxin, a marker indi 
cating increased oxidative stress burden in the intestine. To 
determine if the increased permeability observed in the study 
is associated with increased translocation of intestinal bacte 
rial product, serum endotoxin and LPS-binding protein is 
measured after aspirin challenge. In addition to the more 
commonly-measured endotoxin, LPS-binding protein is 
another index of intestinal permeability-related systemic 
exposure to intestinal bacterial products. Endotoxin is mea 
sured in serum by Limulus Amebocyte Lysate QCL-1000 
(Lonza #50-647U). Serum samples are diluted at a 1:5 ratio 
with LAL reagent water. Lipopolysaccharide binding protein 
(LBP) is measured in plasma using an ELISA kit from Cell 
Sciences Inc (H HK315). 
Example 35 
Serum Complete Metabolic Panel 
A Complete Metabolic Panel is performed to assess the 
effect the treatments on each patient’s basic physiology. Mea 
Surements include Sodium, potassium, chloride, CO., blood 
urea nitrogen, creatinine, glucose, total protein, albumin, cal 
cium, total bilirubin, alkaline phosphatase, aspartate amino 
transferase, alanine aminotransferase, and anion gap. 
Example 36 
Test for Associations 
Associations between host metabolic and immunological 
markers, all taxa in the gut microbiota (analyzed at different 
taxonomic levels) and Bifidobacterium populations are 
assessed by multiple-correlation analysis using Pearson’s 
correlation tests using GraphPad Prism software. Data that 
does not conform to normal distribution and cannot be nor 
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malized with mathematical transformations (i.e.: log 10, 
square root) is analyzed with Spearmen’s rank correlations. 
Example 37 
Outcomes 
The probiotic, GOS, or the synbiotic significantly contrib 
utes to metabolic improvements when compared to the con 
trol placebo. Decreased intestinal hyperpermeability occurs 
in the InVivoSyn Synbiotic group over that of the commer 
cially available synbiotic as well as the probiotics and prebi 
otics alone. A decrease in endotoxemia and an increase in 
LPS-binding protein is observed, as lower levels of plasma 
LBP have been associated with increased exposure to gram 
negative bacteria. 
Either the probiotic, GOS, or the synbiotic significantly 
contributes to metabolic improvements when compared to the 
control placebo (lactose), and a correlation between the Bifi 
dobacterium population and metabolic markers is detectable. 
Example 38 
Statistical Analysis 
Statistical tests for treatment effects on the abundance of 
individual taxonomic ranks is performed by one-way analysis 
of variance (ANOVA) with repeated measures followed by 
TGCAGTCGAA 
TGCGTGACCG 
TGCTCCAGTT 
CCTATCAGCT 
AGGGCGACCG 
GGGAATATTG 
TTCGGGTTGT 
ATAAGCACCG 
CGGAATTATT 
CGCTTAACGG 
ATTCCCGGTG 
TCTCTGGGCC 
CCTGGTAGTC 
TGTCGGAGCC 
AAGAAATTGA 
AAGAACCTTA. 
GGCGGGTTCA 
TCCCGCAACG 
GGGACCGCCG 
CGTCCAGGGC 
GAGCGGATCC 
GGCGGAGTCG 
10 
15 
25 
CGGGATCCCA 
ACCTGCCCCA 
GACCGCATGG 
TGATGGCGGG 
GCCACATTGG 
CACAATGGGC 
AAACCGCTCT 
GCTAACTACG 
GGGCGTAAAG 
TGGATCCGCG 
TAACGGTGGA 
GTCACTGACG 
CACGCCGTAA 
AACGCGTTAA 
CGGGGGCCCG 
CCTGGGCTTG 
CAGGTGGTGC 
AGCGCAACCC 
GGGTCAACTC 
TTCACGCATG 
CTTAAAACCG 
CTAGTAATCG 
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Tukey's post hoc multiple comparisons tests. Apart from 
understanding how each individual taxa is affected by the 
treatments, a collective understanding of how these groups of 
data are affected is investigated by multivariate analyses Such 
as Principal Components Analysis (PCA). For the microbial 
data, PCAS are constructed from a phylogenetic perspective 
using UniFrac software. In addition, one-way ANOVA tests 
followed by Tukey's post hoc tests are performed to identify 
differences in population size and/or metabolic activity in the 
different treatment groups, and especially between Synbiotic 
and probiotic groups. Data is presented as meant-SEM for 
variables that can be considered normally distributed (or 
median and range for variables not normally distributed). 
Group means is compared by ANOVA and post-hoc tests 
except when data is not normally distributed, in which case 
nonparametric analyses of medians is done using the 
Kruskal-Wallis test. Correlation analysis is done using the 
Pearson correlation test for parametric analysis and the Spear 
man correlation test for nonparametric analysis. Chi-square 
tests or Fisher's Exact Tests is used for incidence data. p <0.05 
defines statistical significance. All analyses use SPSS (Chi 
cago, Ill.) or SAS. Data that does not conform to normal 
distribution and cannot be normalized with mathematical 
transformations (i.e., log 10, square root) is analyzed with 
Freidman's non-parametric tests. 
Sequence of 16S rDNA from microbial strain BD1 (SEQID 
NO:8) 
GGAGCTTGCT CCTGGGTGAG. AGTGGCGAAC GGGTGAGTAA 
TACACCGGAA TAGCTCCTGG AAACGGGTGG TAATGCCGGA 
TCCTCTGGGA AAGCTTTTGC GGTATGGGAT GGGGTCGCGT 
GTAACGGCCC ACCATGGCTT, CGACGGGTAG CCGGCCTGAG 
GACTGAGATA CGGCCCAGAC TCCTACGGGA. GGCAGCAGTG 
GCAAGCCTGA TGCAGCGACG CCGCGTGCGG GATGACGGCC 
TGACTGGGAG CAAGCCCTTC GGGGTGAGTG TACCTTTCGA 
TGCCAGCAGC CGCGGTAATA CGTAGGGTGC AAGCGTTATC 
GGCTCGTAGG CGGTTCGTCG CGTCCGGTGT GAAAGTCCAT 
CCGGGTACGG GCGGGCTTGA. GTGCGGTAGG GGAGACTGGA 
ATGTGTAGAT ATCGGGAAGA ACACCAATGG CGAaGGCAGG 
CTGAGGAGCG AAAGCGTGGG GAGCGAACAG GATTAGATAC 
ACGGTGGATG CTGGATGTGG GGACCATTCC ACGGTCTCCG 
GCATCCCGCC TGGGGAGTAC GGCCGCAAGG CTAAAACTCA 
CACAAGCGGC GGAGCATGCG GATTAATTCG ATGCAACGCG 
ACATGTTCCC GACAGCCGTA GAGATACGGT CTCCCTTCGG 
ATGGTCGTCG TCAGCTCGTG TCGTGAGATG TTGGGTTAAG 
TCGCCCTGTG TTGCCAGCAC GTCGTGGTGG GAACTCACGG 
GGAGGAAGGT GGGGATGACG TCAGATCATC ATGCCCCTTA 
CTACAATGGC CGGTACAACG. GGATGCGACA CTGTGAGGTG 
GTCTCAGTTC GGATTGGAGT CTGCAACCCG ACTCCATGAA 
CGGATCAG 
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It is to be understood that, while the methods and compo 
sitions of matter have been described herein in conjunction 
with a number of different aspects, the foregoing description 
of the various aspects is intended to illustrate and not limit the 
scope of the methods and compositions of matter. Other 
aspects, advantages, and modifications are within the scope of 
the following claims. 
Disclosed are methods and compositions that can be used 
for, can be used in conjunction with, can be used in prepara 
tion for, or are products of the disclosed methods and com- 10 
positions. These and other materials are disclosed herein, and 
it is understood that combinations, Subsets, interactions, 
SEQUENCE LISTING 
<16 Os NUMBER OF SEO ID NOS: 8 
<21 Os SEQ ID NO 1 
&211s LENGTH: 18 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Oligonucleotide 
<4 OOs SEQUENCE: 1 
togcgtcygg tdtgaaag 
<21 Os SEQ ID NO 2 
&211s LENGTH: 17 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Oligonucleotide 
<4 OOs SEQUENCE: 2 
cca catccag crtccac 
<21 Os SEQ ID NO 3 
&211s LENGTH: 60 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Oligonucleotide 
<4 OOs SEQUENCE: 3 
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groups, etc. of these methods and compositions are disclosed. 
That is, while specific reference to each various individual 
and collective combinations and permutations of these com 
positions and methods may not be explicitly disclosed, each is 
specifically contemplated and described herein. For example, 
if a particular composition of matter or a particular method is 
disclosed and discussed and a number of compositions or 
methods are discussed, each and every combination and per 
mutation of the compositions and the methods are specifically 
contemplated unless specifically indicated to the contrary. 
Likewise, any Subset or combination of these is also specifi 
cally contemplated and disclosed. 
18 
17 
cgc.ccgcc.gc gC9C9gcggg C9ggg.cgggg gCacgggggg actCctacgg gaggcagcag 60 
<21 Os SEQ ID NO 4 
&211s LENGTH: 14 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Oligonucleotide 
<4 OOs SEQUENCE: 4 
accgcggctg. Ctgg 
<21 Os SEQ ID NO 5 
&211s LENGTH: 50 
&212s. TYPE: DNA 
<213> ORGANISM: Artificial Sequence 
22 Os. FEATURE: 
<223> OTHER INFORMATION: Oligonucleotide 
<4 OOs SEQUENCE: 5 
14 
Cct at CC cct gtgtgccttg gCagt ct cag agagtttgat Cmtggct cag SO 
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What is claimed is: 
1. A foodstuff comprising (a) a composition comprising 
Bifidobacterium adolescentis strain BD1 and GOS and a 
pharmaceutically acceptable carrier selected from the group 
consisting of a liquid carrier, a gel-based carrier, an oleagi 
nous carrier, and an emulsion; and (b) yogurt. 
2. A method for establishing or maintaining a healthy gas 
trointestinal flora in an animal, said method comprising 
administering, enterally, an effective amount of the foodstuff 
of claim 1 to the animal, 
thereby establishing or maintaining a healthy gastrointes 
tinal flora in the animal. 
3. The method of claim 2, wherein said animal is a human. 
4. The method of claim 2, wherein said effective amount is 
from about 10 CFU/day to about 10' CFU/day. 
5. A method for reducing the effects of a gastrointestinal 
disease in an animal, said method comprising administering, 
enterally, an effective amount of the foodstuff of claim 1 to the 
animal, 
thereby reducing the effects of a gastrointestinal disease in 
the animal. 
6. The method of claim 5, wherein said animal is a human. 
7. The method of claim 5, wherein said effective amount is 
from about 10 CFU/day to about 10' CFU/day. 
k k k k k 
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